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Targeted and restricted complement activation 
on acrosome-reacted spermatozoa
Rebecca C. Riley-Vargas,1 Susan Lanzendorf,2 and John P. Atkinson1
1Department of Medicine, Rheumatology Division, and 2Department of Obstetrics and Gynecology,  
Washington University School of Medicine, St. Louis, Missouri, USA.
A specific hypoglycosylated isoform of the complement regulator membrane cofactor protein (MCP; CD46) 
is expressed on the inner acrosomal membrane (IAM) of spermatozoa. This membrane is exposed after the 
acrosome reaction, an exocytosis event that occurs upon contact with the zona pellucida. We initiated this 
investigation to assess MCP’s regulatory function in situ on spermatozoa. Upon exposure of human sper-
matozoa to autologous serum or follicular fluid, we unexpectedly observed that acrosome-reacted sper-
matozoa activated the complement cascade efficiently through C3 but not beyond. Using FACS to simul-
taneously evaluate viability, acrosomal status, and complement deposition, we found that complement 
activation was initiated by C-reactive protein (CRP) and was C1q, C2, and factor B dependent. This pattern 
is consistent with engagement of the classical pathway followed by amplification through the alternative 
pathway. C3b deposition was targeted to the IAM, where it was cleaved to C3bi. Factor H, and not MCP, 
was the cofactor responsible for C3b cleavage. We propose that this localized deposition of complement 
fragments aids in the fusion process between the spermatozoa and egg, in a role akin to that of complement 
in immune adherence. In addition, we speculate that this “targeted and restricted” form of complement 
activation on host cells is a common strategy to handle modified self.
Introduction
Membrane cofactor protein (MCP; CD46) is a widely expressed 
complement regulator with cofactor activity for the factor I– 
mediated cleavage of C3b and C4b (1–4). In addition, MCP is 
a receptor for a growing list of human pathogens, including 
4 viruses (5–10) and 3 bacteria (11, 12). Cross-linking MCP 
produces intracellular signals in diverse cell types including 
macrophages (reviewed in ref. 13), CD4+ T cells (14), and epithe-
lial cells (reviewed in ref. 13). Recently, a deficiency of MCP has 
been linked to the hemolytic uremic syndrome (15, 16).
MCP plays a role in reproduction (reviewed in ref. 13). The MCP 
isoform expressed on spermatozoa is independent of the inherited 
size polymorphism observed in somatic cells (17) and is hypoglyco-
sylated secondary to trimming of the mature N-linked sugars (18). 
Its binding affinity and cofactor activity for C3b and C4b, how-
ever, are comparable to those of MCP expressed by somatic cells 
(2). Expression of MCP by human spermatozoa is restricted to the 
inner acrosomal membrane (IAM) (19, 20), which is exposed follow-
ing binding of spermatozoa to the zona pellucida (Figure 1). Varia-
tions in MCP expression on spermatozoa have been associated with 
infertility (21, 22), and MCP is a target for anti-sperm Abs (23). In 
mice (24), rats (25), and probably guinea pigs (26), MCP is expressed 
exclusively on the IAM of spermatozoa. In these species, another 
related protein, Crry, is widely expressed and performs MCP’s com-
plement-regulatory role (27, 28). Also, Abs against MCP inhibit 
binding to and penetration of zona-free hamster eggs (19, 29, 30) 
and human zona (31) by human spermatozoa. In particular, Abs 
against complement control protein repeat 1 (CCP1), the amino-
terminal CCP, block binding more efficiently than function-block-
ing Abs that bind to CCPs 3 and 4 (30). This observation led us to 
evaluate MCP expression on spermatozoa of New World monkeys 
(32), since they express a splice alternative of MCP lacking CCP1 
on somatic cells (33). This variant may protect against infection by 
measles virus, whose hemagglutinin requires CCP1 to bind MCP 
(33). However, the loss of this repeat does not affect MCP’s comple-
ment-regulatory ability (33–35). Surprisingly, New World monkeys 
retain expression of CCP1 on spermatozoa (32). This conservation 
of structure suggests that MCP participates in fertilization, in addi-
tion to being a complement regulator.
There are several explanations for MCP’s expression on the 
IAM. First, as noted, the retention of CCP1 on spermatozoa of 
New World monkeys and the Ab inhibition data both suggest 
that CCP1 might be playing a role in fertilization independent 
of complement activation (32). Second, in 1993 Anderson et al. 
described a model whereby MCP might be one half of a C3b dimer 
bridge between the spermatozoa and the egg (29). The expres-
sion of complement receptors 1 and 3 on the plasma membrane 
of human eggs adds support to this possibility (29). Third, the 
signaling capabilities of MCP, especially the ability to induce a 
calcium flux (reviewed in ref. 13), may be important on the IAM. 
Fourth, MCP’s complement-regulatory activity could protect 
acrosome-reacted (AR) spermatozoa during the final steps of 
fertilization. Relatedly, the concentration of complement com-
ponents in follicular fluid is equivalent to that in serum (36–39), 
and acrosin, a protease released during the acrosome reaction, can 
cleave C3 (29). However, with anti-sperm Abs and other potential 
complement-activating agents in follicular fluid, it is curious that 
MCP is not also expressed on the plasma membrane of spermato-
zoa as are 2 other complement-regulatory proteins, decay-acceler-
ating factor (DAF) (40) and CD59 (41).
Nonstandard abbreviations used: AR, acrosome-reacted; CCP1, complement con-
trol protein repeat 1; CRP, C-reactive protein; DAF, decay-accelerating factor; GVB++, 
gelatin veronal buffer supplemented with Mg2+ and Ca2+; IAM, inner acrosomal 
membrane; MCP, membrane cofactor protein; mHTF, modified human tubal fluid; 
TRACS, targeted and restricted activation of the complement system.
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To better define the role of MCP on spermatozoa, we set out to 
evaluate MCP in situ as a complement regulator on spermatozoa. 
Early in the course of these experiments, we recognized that AR 
human spermatozoa spontaneously activate complement, and this 
report represents our initial studies of this phenomenon.
Results
The IAM of spermatozoa is exposed following the acrosome reac-
tion. Since MCP’s expression is limited to this structure, the reac-
tion of anti-MCP specific mAb TRA-2-10 with spermatozoa pro-
vides a means to define acrosomal status (i.e., AR or nonreacted). 
Spermatozoa that do not stain for MCP have an intact plasma 
membrane and therefore are not AR. MCP-positive spermatozoa, 
as determined by FACS, have an exposed IAM because they either 
are AR or have a compromised plasma membrane. The latter pos-
sibility was assessed using membrane-impermeable dyes to mark 
nonviable (i.e., membrane-compromised) spermatozoa. Consistent 
with the literature, we found that approximately 25% of the sper-
matozoa in fresh ejaculates were in this category.
To induce the acrosome reaction, human spermatozoa were 
incubated with the calcium ionophore A23187. This reagent con-
verts between 30% and 70% of viable, nonreacted spermatozoa 
to AR spermatozoa. A representative histogram of MCP expres-
sion by ionophore-treated spermatozoa is shown in Figure 2A. 
Using primary labeled Abs, there is approximately a 1-log shift in 
MCP expression following incubation of spermatozoa with the 
ionophore. This shift represents exposure of the IAM and hence 
MCP. In this sample, approximately 60% of the spermatozoa were 
induced to acrosome-react. A small percentage of cells (approxi-
mately 20% for this donor) in the untreated sample were also 
MCP positive. This is expected and represents the population of 
spermatozoa that have spontaneously undergone the acrosome 
reaction. The proportion of spontaneously AR spermatozoa var-
ied among donors and ranged from 20% to 45% in the 4 donors 
regularly used for these studies.
To examine the complement-regulatory activity of MCP on 
spermatozoa in situ, experiments were designed in which sper-
matozoa were to be sensitized with anti-sperm Abs. As a control, 
unsensitized ionophore-treated and untreated spermatozoa were 
exposed to 10% autologous serum and analyzed by FACS. An 
mAb against C3d was used as a marker of complement activation. 
Unexpectedly, this mAb reacted with unsensitized, ionophore-
treated spermatozoa. This suggests that, following the acrosome 
reaction, spermatozoa activate complement (Figure 2B). To fur-
ther analyze this finding, we stained for MCP and C3d on the 
same population. There was a direct relationship between MCP 
staining and presence of C3d antigen (Figure 3A). No staining for 
C3d was observed on viable nonreacted spermatozoa (Figure 3A, 
box in top left panel). This result further establishes that C3-derived 
fragments deposit on AR spermatozoa. Although there was vari-
ability in the percentage of AR spermatozoa among individu-
als, the parallel relationship between MCP and C3d staining 
was observed for each donor (Figure 3A), and the pattern was 
reproducible for the same donor. The deposition on MCP-posi-
tive (AR) spermatozoa was greater (mean ± SD fluorescence for 
4 donors was 313 ± 65) than on spermatozoa incubated with 
heat-inactivated serum (mean ± SD fluorescence for 4 donors 
Figure 1
Schematic representation of the acro-
some reaction of human spermatozoa. 
(A) The acrosome reaction of capacitated 
spermatozoa occurs after binding to the 
zona pellucida. (B) Upon this event, the 
outer acrosomal membrane fuses with the 
plasma membrane, releasing the acro-
some contents. (C) MCP is expressed on 
the IAM and thus is exposed following the 
acrosome reaction.
Figure 2
FACS profiles of MCP and C3d on ionophore-treated spermatozoa. (A) 
Calcium ionophore induces the acrosome reaction, exposing MCP to 
the fluorescently labeled Ab. Approximately 20% of spermatozoa spon-
taneously undergo the acrosome reaction in the untreated sample. The 
antibody used was Alexa Fluor 488–labeled TRA-2-10 (mAb against 
MCP). (B) Spermatozoa exposed to calcium ionophore activate com-
plement monitored by C3d deposition. The antibody used was Alexa 
Fluor 647–labeled mAb against C3d. A representative experiment (out 
of about 50 experiments) is shown.
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was 34 ± 17, which is equivalent to that for the no-Ab control 
samples) (Figure 3B). Complement deposition was rapid, being 
maximal by 15 minutes, and there was no decrease in spermato-
zoa viability at 15 or 30 minutes. In addition, after 15 minutes 
only approximately 1% of the viable C3-positive spermatozoa 
were positive for C5b-9 neoepitope (data not shown), and there 
was no decrease in spermatozoa motility. Also, we were not able 
to detect C5b or C9 deposition on ionophore-treated sperma-
tozoa by Western blot, even if the cofactor activity of MCP was 
blocked with an mAb (data not shown). These data establish that 
the complement deposition on AR spermatozoa is restricted to 
the early complement components (through C3) and does not 
decrease spermatozoa viability.
Following binding to the zona pellucida in the fallopian tubes, 
which induces the acrosome reaction, the IAM of spermatozoa 
is exposed to follicular fluid. We obtained neat follicular fluid 
from 1 donor and follicular fluid diluted approximately 1:10 
from several donors to determine whether the complement 
deposition occurs in this physiologically relevant source of com-
plement. We incubated both untreated and ionophore-treated 
spermatozoa with follicular fluid and observed deposition on 
AR spermatozoa (Figure 4). Results were similar whether neat 
or diluted follicular fluid was used. The mean (± SD) fluores-
cence for C3d was 263 ± 19 and 219 (see legend to Figure 4) for 
spermatozoa from 2 different donors incubated with follicular 
fluid, compared with 387 ± 17 and 229 ± 39, respectively, for 
spermatozoa incubated with 10% serum.
To evaluate the pathway responsible for complement acti-
vation, deficient, depleted, and treated human sera were used 
(Table 1). Deposition of C3 fragments was prevented if the 
autologous serum was heat-inactivated or treated with EDTA. 
These conditions inactivate the proteases in the complement 
cascade but leave C3 intact. In these conditions there was no 
complement activation; this indicates that the initial activation 
Figure 3
FACS analysis of C3d deposition on viable spermatozoa exposed to 10% autologous serum. (A) Each FACS plot represents a single donor and 
is gated on viable spermatozoa. The correlation between the acrosome reaction (as measured by MCP staining) and complement deposition 
(as measured by C3d staining) is observed in all 4 donors. The inset box in each FACS plot represents the MCP- and C3d-negative population. 
(B) Mean C3d fluorescence of viable AR and non-AR (NAR) spermatozoa exposed to 10% normal human serum (NHS) or heat-inactivated (HI) 
human serum. Mean ± SD for a minimum of 3 experiments per donor is shown.
Figure 4
FACS analysis of viable spermatozoa exposed to follicular fluid. (A) 
Each FACS plot represents a single donor and is gated on viable sper-
matozoa. The correlation between the acrosome reaction (as mea-
sured by MCP staining) and complement deposition (as measured by 
C3d deposition) is observed for both donors. Each FACS plot is repre-
sentative of 10 experiments. (B) Mean C3d fluorescence of viable sper-
matozoa exposed to follicular fluid (FF). Because of the limited quantity 
of neat follicular fluid, only 1 experiment using donor 1 was performed. 
Data for donor 3 are the mean ± SD of 3 experiments.
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of C3 is unlikely to be secondary to cleavage by an acrosomal 
protease such as acrosin (29). Deposition was not observed with 
C1q-depleted serum; this rules out the lectin pathway as a con-
tributing cascade and establishes a role for the classical pathway. 
This conclusion was substantiated by the finding that neither 
C2-deficient sera nor Mg2+-EGTA–treated serum permitted 
complement activation. Factor B–depleted sera also prevented 
C3 fragment deposition, demonstrating a requirement for the 
alternative pathway. As anticipated, a deficiency of a late com-
plement component, in this case C7, did not affect C3 fragment 
deposition. Taken together, these data support initial comple-
ment activation via the classical pathway and then amplifica-
tion of the activation process through the feedback loop of the 
alternative pathway.
There are several means to initiate complement activation 
through C1q. First, we examined spermatozoa, following expo-
sure to serum, for the presence of natural Ab. FACS, ELISA, 
and confocal microscopy using Abs against human IgM or IgG 
did not detect Ab bound to AR spermatozoa (data not shown). 
Second, because C-reactive protein (CRP) initiates the classical 
pathway via C1q (42) and is present in follicular fluid at levels 
similar to those in serum (43, 44), we performed Western blots 
and FACS analysis on ionophore-treated spermatozoa exposed 
to 10% autologous serum. A CRP-specific band at 25 kDa was 
observed in AR spermatozoa exposed to serum (Figure 5A). The 
fainter band in the untreated sample is likely derived from spon-
taneously AR spermatozoa (typically 10–20% of the spermato-
zoa). In addition, FACS showed CRP binding to AR spermato-
zoa that had been exposed to 10% serum (Figure 5B). Because of 
these results, CRP was absorbed from serum with beads linked 
to phosphocholine. The resulting serum had a reduced ability 
to activate complement on AR spermatozoa (Figure 5C). These 
data demonstrate that CRP is responsible for initiating the clas-
sical complement pathway on AR spermatozoa.
Next, we used confocal microscopy to define the location of the 
complement fragments. An mAb against MCP, TRA-2-10, was used 
to identify the IAM (Figure 6A). After spermatozoa were exposed to 
10% serum, an mAb against C3d exclusively stained the IAM (Fig-
ure 6, B and C). This demonstrates that complement activation is 
restricted to the IAM and supports the FACS profile of Figure 3 in 
which AR spermatozoa are shown to activate complement.
The Ab used in the FACS and confocal experiments recog-
nizes C3d, an epitope present in all membrane-bound cleavage 
fragments of C3 (Figure 7A). To determine the complement 
fragments containing C3d on the IAM, we performed Western 
blots with a polyclonal Ab against C3. In the lane derived from 
ionophore-treated spermatozoa, the α′ chain is cleaved and α2 is 
present, indicating that the C3b has been cleaved to C3bi (Fig-
ure 7B). As expected, the α1 band is barely visible, as it would 
be attached via an ester linkage to proteins of varying molecular 
weights expressed on the IAM. Since MCP is a cofactor for the 
Table 1
Complement activation by AR spermatozoa under different 
serum conditions
Serum C3d Fluorescence (mean ± SD)
10% NHS Yes 313 ± 65
Heat-inactivated No 34 ± 17
EDTA No 31 ± 18
MgEGTA No 32 ± 17
C1q-depleted No 29 ± 14
C2-deficient No 33 ± 12
Factor B–depleted No 32 ± 18
C7-deficient Yes 289 ± 54
Calcium ionophore–treated human spermatozoa were exposed for 15 
minutes to the sera noted above and then incubated with an mAb to C3d 
and analyzed by FACS. Heat inactivation and EDTA treatment block all 
complement activation pathways. Mg++EGTA-treated serum, C1q-deplet-
ed serum, and C2-deficient serum prevent classical-pathway activation. 
Factor B–depleted serum prevents alternative-pathway activation. The 
data in the first, second, and last rows represent 10 separate experi-
ments, while the results in the other rows are from 2 experiments. NHS, 
normal human serum.
Figure 5
Analysis of CRP binding to AR spermatozoa. (A) Western blot of human spermatozoa. Ionophore-treated or untreated spermatozoa were exposed 
to either 10% normal or EDTA-treated autologous human serum. Lysates were separated in reducing conditions by SDS-PAGE on a 10–20% 
Tris-glycine gel. The primary antibody used was polyclonal goat anti–human CRP at 1:1,000 dilution. CRP is a pentamer composed of five 25-kDa 
subunits. (B) FACS analysis of CRP on spermatozoa. Ionophore-treated spermatozoa were exposed to either 10% normal or heat-inactivated 
autologous human serum. The primary antibody used was polyclonal goat anti–human CRP at 1:1,000 dilution. The secondary antibody used 
was FITC-linked rabbit anti-goat at 1:10,000 dilution. (C) FACS analysis of spermatozoa exposed to CRP-absorbed serum. Serum was preincu-
bated with immobilized phosphorylcholine to absorb CRP. Spermatozoa were then exposed to 10% normal serum, 10% CRP-absorbed serum, 
or EDTA-treated human serum. Complement activation was measured by C3d fluorescence of viable AR spermatozoa.
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cleavage of C3b to C3bi, we blocked MCP’s cofactor activity with 
the mAb GB24 (45). TRA-2-10, used as a control, binds to CCP1 
and does not block function (45). Neither Ab inhibited the cleav-
age of C3b to C3bi (Figure 7B). Factor H, a soluble complement 
regulator that is present in follicular fluid at levels comparable 
to those in serum (39), also cleaves C3b to C3bi. When the mAb 
MH-10, which blocks the function of factor H, was used (46), the 
cleavage of C3b was inhibited (Figure 7B). Thus, factor H was 
responsible for the majority of the C3b cleavage.
Discussion
The acrosome reaction is a large exocytosis event that is induced 
in vivo when spermatozoa bind to the zona pellucida of the egg 
(Figure 1). This reaction releases enzymes that degrade the protein 
matrix of the zona and thereby allows the spermatozoa to trans-
verse the zona and enter the perivitelline space. Our data show that 
when this event occurs spontaneously or is induced in vitro, com-
plement activation is triggered, resulting in deposition of comple-
ment fragments specifically on the IAM. Deposition was depen-
dent on C1q, C2, and factor B, consistent with initial activation 
of the classical pathway followed by engagement of the alternative 
pathway amplification loop. The observation that complement 
deposition on viable AR spermatozoa was C1q dependent, but 
Ab independent, led us to investigate CRP as the activating pro-
tein, because this lectin initiates the complement cascade 
through C1q (42). Also, CRP concentrations in follicular 
fluid are comparable to those in serum and fluctuate with 
the female cycle, peaking during ovulation (43, 44). Fur-
ther, since CRP activates complement on apoptotic cells 
(42, 47) and nonviable spermatozoa activate complement 
(48), we used 3 different nucleic dyes and examined motili-
ty to establish that viable, motile, AR spermatozoa activate 
complement. CRP bound specifically to the IAM of viable, 
AR spermatozoa. Consistent with its biochemical proper-
ties, heat inactivation or EDTA treatment of serum abro-
gated the binding of CRP to AR spermatozoa. In addition, 
serum incubated with phosphocholine beads to absorb 
CRP prevented C3d deposition. Taken together, these data 
indicate that CRP mediates the complement activation on 
the IAM of AR spermatozoa.
At first glance, complement activation on viable, AR 
spermatozoa is perplexing. If the membrane attack com-
plex were to be formed on the IAM, there is the risk of 
membrane perturbation and possibly lysis of sperma-
tozoa in the final steps of fertilization. Second, spermatozoa 
opsonized with C3b and C3bi are subject to immune adherence 
and phagocytosis. Third, the anaphylatoxins produced during 
complement activation could produce an inflammatory cell 
influx. Each of these points will now be addressed.
Surprisingly, complement activation on AR spermatozoa did 
not lead to loss of motility or cell death. These data suggest 
that the complement deposition on AR spermatozoa is largely 
restricted to early complement components (C1, C4, C2, and C3) 
and does not efficiently proceed to the membrane attack com-
plex. The presence of 2 complement regulators on the IAM, MCP 
(19, 20, 49) and DAF (40), makes it difficult to envision spon-
taneous complement deposition on this membrane. However, 
activation by the classical pathway can overwhelm these regula-
tory proteins (46). Their presence, though, is in concert with the 
hypothesis of “restricted activation” (see below) and may account 
Figure 6
Confocal microscopy of AR spermatozoa exposed to 10% serum. Spermatozoa 
were incubated with calcium ionophore to induce the acrosome reaction and 
then exposed to 10% autologous serum. (A) The mAb TRA-2-10 labeled with 
Alexa Fluor 488 recognizes MCP on the IAM. (B) An mAb to C3d labeled with 
Alexa Fluor 647 binds to the IAM. (C) Overlay of A and B. C3d deposition is 
limited to the IAM. Magnification, ×63.
Figure 7
Western blot of C3 fragments on AR spermatozoa. (A) Diagram of C3 
structure. C3 is composed of 2 chains, α and β. Upon activation, C3a 
is released, leaving the truncated α′ chain of C3b. Factor I cleaves 
the α′ chain in 2 locations, creating the fragments α1, α2, and C3f 
(pictured in yellow). The interchain and intrachain disulfide bonds are 
also shown. (B) Spermatozoa were incubated with calcium ionophore 
to induce the acrosome reaction, exposed to 10% autologous human 
serum, lysed, absorbed with Sepharose linked to mAb against C3d, 
eluted in reducing SDS buffer, and loaded on a 10–20% gel. Lanes 1–3, 
C3 standards; lane 4, AR spermatozoa incubated with 10% serum; 
lane 5, spermatozoa were preincubated with the mAb TRA-2-10 and 
then exposed to 10% serum; lane 6, spermatozoa were preincubated 
with the mAb GB24, which blocks the complement-regulatory function 
of MCP; lane 7, serum was preincubated with the mAb MH-10, which 
blocks the complement-regulatory function of factor H (46).
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for why the late complement components are inefficiently depos-
ited on viable, AR spermatozoa. These results are also consistent 
with studies showing that complement activation by CRP does 
not deplete the late complement components (42, 47).
Nonviable spermatozoa are known to activate the complement 
cascade, producing the anaphylatoxins C3a and C5a (50, 51). 
These peptides are potent chemotaxins and cellular activators 
that could serve to attract neutrophils to clear the female repro-
ductive tract of nonviable spermatozoa (50, 51). It is also likely 
that these neutrophils assist in eliminating pathogens introduced 
to the female genital tract. In concert with this idea, the concen-
tration of C3 in follicular fluid increases during ovulation (52). 
Under this scenario, C3b-opsonized viable spermatozoa might 
be at risk for phagocytosis. However, complement activation on 
AR spermatozoa occurs following binding to the zona pellucida 
of the egg. There is limited, if any, opportunity for these sperma-
tozoa to interact with a phagocyte after entering the zona pel-
lucida. As outlined above, complement activation on nonviable 
spermatozoa is likely a means of affecting their clearance. Viable 
AR spermatozoa, in contrast, induce restricted targeted comple-
ment activation for a different purpose, presumably to facilitate 
sperm-egg interactions.
The purpose of complement activation on AR spermatozoa 
may be to coat the IAM with opsonins. Complement fragments 
on spermatozoa would then facilitate egg binding, similar to 
complement’s role in mediating immune adherence. Comple-
ment receptors 1 and 3 are expressed on the plasma membrane 
of the egg (29). Complement is visualized as part of a highly 
redundant process to facilitate sperm-egg binding. This line of 
reasoning could explain why the mice deficient in C3 (53, 54), C4 
(55), MCP (24), or integrins (56) are fertile. We hypothesize that 
dismantling parts of the complement system in these mice elimi-
nates a supportive pathway for fertilization but does not obliter-
ate it. Hence, by the broad measurement of litter size, there is no 
defect observed. This hypothesis provides the impetus to further 
assess the sperm-egg binding in these deficient mouse strains.
The possibility of complement activation fragments interact-
ing with complement receptors to facilitate sperm-egg binding 
was first proposed in 1993 by Anderson and colleagues (29). In 
that pivotal report, several mechanisms were identified whereby 
spermatozoa could be coated with C3b, including alternative path-
way activation, direct cleavage of C3 by the protease acrosin, and 
binding of dimeric C3b to complement regulators/receptors. We 
have extended and refined this study, particularly in relation to 
the complement activation on AR spermatozoa. In an experimen-
tal system that quantitatively assesses viability, acrosomal status, 
and complement deposition using follicular fluid, we demonstrate 
that CRP binds to the IAM of viable AR spermatozoa and initiates 
the classical pathway. These results are consistent with a “seeding” 
of C3b by the classical pathway that in turn triggers the feedback 
loop of the alternative pathway. The bound C3b is rapidly con-
verted to C3bi by factors H and I. We therefore hypothesize that 
C3bi, a ligand for integrin-related complement receptors, facili-
tates sperm-egg interactions.
Complement activation on viable AR spermatozoa, whether 
spontaneous or induced by the calcium ionophore, has several 
features that distinguish it from complement activation on for-
eign antigens. First, on spermatozoa, the fragment deposition 
is targeted to a specific cellular location. Second, complement 
activation is restricted beyond the C3 step, thereby limiting the 
formation of membrane-damaging pores and release of the C5a 
chemotactic factor and anaphylaxation. Third, the overall mag-
nitude of activation up to the C3 step appears to be more tightly 
controlled. It is as if this system on spermatozoa was specifically 
designed to allow a measured amount of C3b to be deposited at 
a specific site for a critical purpose. This concept of complement 
activation on self tissue (CAST), which we propose to also call 
TRACS for highly targeted and restricted activation of the com-
plement system, is not well described as such in the literature; 
however, we believe it is a common and underappreciated func-
tion of the complement system’s interaction with self tissue. In 
conditions like apoptosis, ischemia/reperfusion injury, and prob-
ably other types of alterations in host cell structure, TRACS is a 
preferable means to activate the complement system. In contrast 
to the desirable explosion of the cascade on microbes, comple-
ment activation on an apoptotic cell is less robust, yet sufficient 
to facilitate the safe and relatively noninflammatory removal of 
altered self (42, 47). In the setting of ischemia/reperfusion inju-
ry, one can envision a gradient of complement activation that 
correlates with the degree of cellular damage. In this example, 
the goal is to rapidly and safely remove dead and dying tissue in 
order to enhance wound healing and promote tissue sterility. As 
previously outlined, activation on spermatozoa may represent a 
situation whereby complement activation plays a role in repro-
duction. In these settings, regulatory proteins are present on the 
cells, and it is likely the ratio of the strength and type of activa-
tion to the quantity and efficiency of the regulators that deter-
mines the outcome. Complement activation on the membrane of 
Mycobacterium tuberculosis may represent an abuse of this type of 
a system (57). This pathogen salvages the catalytic complement 
fragment C2a of the classical pathway C3 convertase and uses it 
to then deposit a limited amount of C3b on its membrane. This 
deposition of C3b aids the pathogen by facilitating internaliza-
tion through complement receptors.
In these experiments, one question that we set out to address 
was the role of MCP on the IAM of spermatozoa. A possibility 
entertained was that MCP regulated complement on the IAM. 
However, blocking MCP with mAbs does not enhance or dimin-
ish C3 fragment deposition, and MCP is not responsible for the 
cleavage of C3b to C3bi. MCP efficiently regulates the C5 conver-
tase (47, 58). We therefore favor the idea that, along with DAF, 
CD59, factor H, and CRP, MCP limits complement activation, 
especially C5 convertase activity. However, blocking MCP func-
tion with mAb did not increase C5b-9 deposition. Activation of 
complement via CRP leads to restricted C5b-9 activation (42, 47), 
so MCP’s role in this situation may be redundant. A second pos-
sible role is that MCP may mediate a direct binding event between 
the spermatozoa and the egg. MCP has been shown to associate 
with the tetraspan CD9 on macrophages (59) and other cell types 
(60). The targeted disruption of CD9 in mice results in infertility 
due to the inability of spermatozoa to bind to the egg (61, 62). 
Perhaps integrins associated with MCP, CD9, and tetraspans 
mediate binding between the spermatozoa and the egg. Alterna-
tively, as previously suggested, MCP may be one part of a C3b 
dimer bridge with complement receptors on the egg (29), analo-
gous to complement’s role in mediating immune adherence. A 
third possibility is that complement deposition cross-links MCP 
on the IAM, inducing MCP-mediated signaling events important 
for fertilization (signaling through MCP is reviewed in ref. 13). A 
fourth possibility is that MCP influences membrane fluidity, as 
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evidenced by a role for MCP in the acceleration of the rate of the 
acrosome reaction in MCP-deficient mice (24).
In summary, viable AR spermatozoa activate complement. 
The complement deposition is triggered by CRP activation of 
the classical pathway, followed by amplification of C3 deposi-
tion through the alternative pathway feedback loop. Comple-
ment deposition is localized to the IAM and is curtailed beyond 
the C3 activation step. The purpose of this reaction remains 
problematic. However, we propose that this type of targeted and 
restricted complement activation is a common phenomenon on 
modified self tissue.
Methods
Spermatozoa samples. Spermatozoa samples were obtained with informed 
consent, and all studies were approved by the Washington University 
Human Studies Committee (protocol number 94-0420). Human sper-
matozoa samples were repeatedly obtained from 4 healthy donors 
ranging in age from 18 to 38. Fresh ejaculates were allowed to liquefy 
at room temperature for 45 minutes, and then washed twice with modi-
fied human tubal fluid (mHTF) supplemented with 5% serum substitute 
supplement (Irvine Scientific) and 5% HSA (100 mg/ml) (Irvine Scien-
tific). Unless stated otherwise, centrifugation steps were performed at 
200 g for 10 minutes at 4°C.
Serum preparation. Blood samples were obtained from donors that pro-
vided informed consent, and all studies were approved by the Washing-
ton University Human Studies Committee (protocol number 94-0420). 
Human blood was collected in glass tubes and allowed to clot at room 
temperature for 30 minutes. Samples were then centrifuged at 200 g. The 
serum was placed in sterile 1.5-ml microcentrifuge tubes and maintained 
at –20°C for short-term or –70°C for long-term storage.
Follicular fluid collection. Follicular fluid samples were obtained from 
patients that provided informed consent, and all studies were approved 
by the Washington University Human Studies Committee (protocol 
number 02-1004). Follicular fluids were collected from patients under-
going in vitro fertilization. Ovarian stimulation was performed using 
gonadotropins in combination with a gonadotropin-releasing hormone 
(GnRH) antagonist or GnRH agonist according to established proto-
cols. Serum estradiol was measured on cycle days 3, 5, and 7 and daily 
thereafter until retrieval. Vaginal ultrasound was performed daily from 
cycle day 7 onward. Human chorionic gonadotropin (5,000–10,000 IU, 
Profasi; Serono Inc.) was administered intramuscularly when 3 or more 
follicles were at least 16 mm in largest diameter. Transvaginal follicular 
aspiration was performed 35–36 hours later. Follicles were aspirated 
using a Wallace catheter (Irvine Scientific), and contents of each follicle 
were collected into a 15-ml tube (Falcon 2057; Cardinal Health) contain-
ing approximately 1.0 ml of mHTF (Irvine Scientific) supplemented with 
0.3 ml of sodium heparin. After the removal of oocytes, the follicular 
fluids were stored at 4°C until processed. To collect pure follicular fluid, 
the dominant follicle of a patient(s) was aspirated directly into a tube 
that did not contain mHTF.
Acrosome reaction. The acrosome reaction was induced by incubation 
of spermatozoa in supplemented mHTF media with 20 mM calcium 
ionophore A23187 (Sigma-Aldrich) at 37°C for 45 minutes.
Antibodies. The mouse anti-MCP mAb TRA-2-10 was prepared at Wash-
ington University. The mouse mAb against factor H (MH-10) was donat-
ed by J. Lambris (University of Pennsylvania, Philadelphia, Pennsylvania, 
USA). The mouse mAbs against human C3d and C5b-9 neoantigen were 
purchased from Quidel Corp. The polyclonal goat anti–human C9 Ab 
was purchased from Quidel Corp. The polyclonal goat anti–human C5 
Ab was purchased from Advanced Research Technologies. Polyclonal 
goat anti–human CRP was purchased from Affinity BioReagents. HRP-
conjugated rabbit anti-goat IgG (Sigma-Aldrich) was used as the second-
ary Ab for Western blotting. Zenon labeling kits (Invitrogen Corp.) were 
used to link fluorochromes (Alexa Fluor 488 or Alexa Fluor 647) to pri-
mary Abs according to the manufacturer’s instructions (1 μg of primary 
Ab was used per labeling reaction). One microgram of TRA-2-10 was 
used per 1 × 106 spermatozoa, and 1 μg of either the C3d or the C5b-9 
mAb was used per 2 × 106 spermatozoa for both FACS (BD Biosciences) 
and confocal microscopy.
Complement deposition. AR or untreated spermatozoa were resuspended in 
gelatin veronal buffer supplemented with Mg2+ and Ca2+ (GVB++) (Sigma-
Aldrich). After incubation in 10% autologous serum or follicular fluid for 
15 minutes at 37°C, the samples were washed with supplemented mHTF 
media. Gelatin veronal buffer supplemented with 10 mM EDTA (Sigma-
Aldrich) and gelatin veronal buffer supplemented with 10 mM EGTA and 
7 mM magnesium chloride were also used. Sera were heat-inactivated by 
30 minutes of incubation at 56°C. Sources of the C2- and C7-deficient sera 
were as described in ref. 46. C1q- and factor B–depleted sera were obtained 
from Advanced Research Technologies.
Viability dyes. Propidium iodide (Invitrogen Corp.), SYTOX Green 
(Invitrogen Corp.), and SYBR 14 (Invitrogen Corp.) were used to assess 
viability according to the manufacturer’s instructions. Results were com-
parable with all 3 dyes, but the different fluorescent ranges of the 3 dyes 
allowed for flexibility in fluorochrome usage.
FACS analysis. Spermatozoa, after exposure to a complement source, 
were incubated with Zenon-labeled primary Abs (described above) for 
30 minutes at 37°C in supplemented mHTF and then washed twice. 
Flow cytometry was performed with a FACSCalibur (BD Biosciences) 
using forward and side scatter thresholds optimized for spermatozoa. 
A minimum of 10,000 events were collected per sample. Samples were 
gated on viable spermatozoa.
Lysates. Spermatozoa were resuspended in lysis buffer (PBS containing 
1% NP-40, 0.05% SDS, and Complete protease inhibitor cocktail tablets 
[Roche Diagnostics Corp.]) and incubated for 30 minutes at 4°C. Samples 
were centrifuged at 13,500 g for 15 minutes at 4°C. Supernatants were 
transferred to 1.5-ml microcentrifuge tubes and stored at –20°C.
Immunoabsorption. Polyclonal goat anti–human C3 was coupled to CNBr-
activated Sepharose (Amersham Biosciences) according to the manufac-
turer’s suggestion. Spermatozoa lysate (50 μl), coupled Sepharose (50 μl), 
protease inhibitor tablets (Roche Diagnostics Corp.), and cell lysis buffer 
were combined and incubated at 4°C overnight with “end over end” mixing. 
The Sepharose beads were next washed 3 times with 0.3% NP-40. Eluates, 
obtained by boiling of the Sepharose beads in SDS loading buffer, were 
used for Western blotting as described below.
Western blotting. Cell lysates were separated in a 10–20% SDS-polyacrylamide 
gel under reducing conditions and then transferred onto nitrocellulose mem-
branes using the NOVEX MiniCell II wet blotting system (Invitrogen Corp.). 
The membranes were blocked with 5% nonfat dry milk powder in 1× Tris-buff-
ered saline (TBS) and 0.05% Tween-20 (TBS-T) (Sigma-Aldrich) overnight at 
4°C. After 3 washes in TBS-T, the membranes were incubated in blocking buf-
fer for 1 hour at 37°C with either purified polyclonal goat anti-CRP (1:1,000) 
or polyclonal goat anti-C3 Ab (1:7,500). Blots were washed 3 times and then 
incubated in blocking buffer for 1 hour at room temperature with HRP-con-
jugated rabbit anti-goat IgG secondary Ab (Sigma-Aldrich) (1:10,000). After 
washing, the signals were developed using the enhanced chemiluminescence 
kit from Pierce Biotechnology Inc. The bands were visualized by exposure of 
the membranes to BioMax MR film (Eastman Kodak Co.).
ELISA for human IgM. The Microwell ELISA (Diagnostic Automation Inc.) 
was used to assess total human IgM in spermatozoa lysates according to 
the manufacturer’s instructions.
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Confocal microscopy. Spermatozoa were incubated in the fluid phase with 
Zenon-labeled primary Abs (described above) for 30 minutes at 37°C in 
supplemented mHTF. After the samples were washed twice with supple-
mented mHTF media, a 1:1 dilution of sample and ProLong Antifade 
Reagent (Invitrogen Corp.) was placed on a slide and analyzed with an LSM 
510 META confocal microscope (Carl Zeiss Inc.).
CRP absorption. Immobilized p-aminophenyl phosphorylcholine beads 
(150 μl; Pierce Biotechnology Inc.) were added to human serum diluted 
1:10 with GVB++ buffer. The samples were incubated at room temperature 
for 30 minutes with gentle mixing. After centrifugation at 200 g for 5 
minutes, the supernatant was removed and used as a complement source 
for FACS experiments.
Acknowledgments
We thank Madonna Bogacki for excellent secretarial support and 
Wandy Beaty from the Washington University Imaging Core for guid-
ance in confocal microscopy. This work was supported by NIH grant 
AI37618-10.
Received for publication August 30, 2004, and accepted in revised 
form March 1, 2005.
Address correspondence to: John P. Atkinson, Washington Uni-
versity School of Medicine, 660 South Euclid Avenue, Campus 
Box 8045, St. Louis, Missouri 63110, USA. Phone: (314) 362-8391; 
Fax: (314) 362-1366; E-mail: jatkinso@im.wustl.edu.
 1. Seya, T., Turner, J., and Atkinson, J.P. 1986. Puri-
fication and characterization of a membrane pro-
tein (gp45-70) that is a cofactor for cleavage of 
C3b and C4b. J. Exp. Med. 163:837–855.
 2. Ballard, L.L., Bora, N.S., Yu, G.H., and Atkinson, 
J.P. 1988. Biochemical characterization of mem-
brane cofactor protein of the complement sys-
tem. J. Immunol. 141:3923–3929.
 3. Seya, T., and Atkinson, J.P. 1989. Functional prop-
erties of membrane cofactor protein of comple-
ment. Biochem. J. 264:581–588.
 4. Oglesby, T.J., Allen, C.J., Liszewski, M.K., White, 
D.J., and Atkinson, J.P. 1992. Membrane cofactor 
protein (CD46) protects cells from complement-
mediated attack by an intrinsic mechanism. 
J. Exp. Med. 175:1547–1551.
 5. Dorig, R.E., Marcil, A., Chopra, A., and Richard-
son, C.D. 1993. The human CD46 molecule is a 
receptor for measles virus (Edmonston strain). 
Cell. 75:295–305.
 6. Naniche, D., et al. 1993. Human membrane cofac-
tor protein (CD46) acts as a cellular receptor for 
measles virus. J. Virol. 67:6025–6032.
 7. Manchester, M., Liszewski, M.K., Atkinson, J.P., 
and Oldstone, M.B.A. 1994. Multiple isoforms 
of CD46 (membrane cofactor protein) serve as 
receptors for measles virus. Proc. Natl. Acad. Sci. 
U. S. A. 91:2161–2165.
 8. Santoro, F., et al. 1999. CD46 is a cellular receptor 
for human herpesvirus 6. Cell. 99:817–827.
 9. Segerman, A., et al. 2003. Adenovirus type 
11 uses CD46 as a cellular receptor. J. Virol. 
77:9183–9191.
 10. Gaggar, A., Shayakhmetov, D.M., and Lieber, A. 
2003. CD46 is a cellular receptor for group B 
adenoviruses. Nat. Med. 9:1408–1412.
 11. Okada, N., Liszewski, M.K., Atkinson, J.P., and 
Caparon, M. 1995. Membrane cofactor protein 
(CD46) is a keratinocyte receptor for the M pro-
tein of the group A streptococcus. Proc. Natl. Acad. 
Sci. U. S. A. 92:2489–2493.
 12. Kallstrom, H., Liszewski, M.K., Atkinson, J.P., and 
Jonsson, A.B. 1997. Membrane cofactor protein 
(MCP or CD46) is a cellular pilus receptor for 
pathogenic Neisseria. Mol. Microbiol. 25:639–647.
 13. Riley-Vargas, R.C., and Atkinson, J.P. 2003. Expres-
sion of membrane cofactor protein (MCP; CD46) 
on spermatozoa: just a complement inhibitor? 
Modern Aspects of Immunobiology. 3:75–78.
 14. Kemper, C., et al. 2003. Activation of human CD4+ 
cells with CD3 and CD46 induces a T-regulatory 
cell 1 phenotype. Nature. 421:388–392.
 15. Richards, A., et al. 2003. Mutations in human 
complement regulator, membrane cofactor pro-
tein (CD46), predispose to development of famil-
ial hemolytic uremic syndrome. Proc. Natl. Acad. 
Sci. U. S. A. 100:12966–12971.
 16. Noris, M., et al. 2003. Familial haemolytic urae-
mic syndrome and an MCP mutation. Lancet. 
362:1542–1547.
 17. Cervoni, F., et al. 1992. Identification and charac-
terization of membrane cofactor protein (MCP) on 
human spermatozoa. J. Immunol. 148:1431–1437.
 18. Riley, R.C., Kemper, C., Leung, M., and Atkinson, 
J.P. 2002. Characterization of human membrane 
cofactor protein (MCP; CD46) on spermatozoa. 
Mol. Reprod. Dev. 62:534–546.
 19. Anderson, D.J., Michaelson, J.S., and Johnson, 
P.M. 1989. Trophoblast/leukocyte-common anti-
gen is expressed by human testicular germ cells 
and appears on the surface of acrosome-reacted 
sperm. Biol. Reprod. 41:285–293.
 20. Fenichel, P., et al. 1990. Localization and charac-
terization of the acrosomal antigen recognized by 
GB24 on human spermatozoa. Mol. Reprod. Dev. 
27:173–178.
 21. Kitamura, M., et al. 1997. Possible association of 
infertility with sperm-specific abnormality of 
CD46. J. Reprod. Immunol. 33:83–88.
 22. Nomura, M., et al. 2001. Genomic analysis of 
idiopathic infertile patients with sperm-spe-
cific depletion of CD46. Exp. Clin. Immunogenet. 
18:42–50.
 23. Jiang, H., and Pillai, S. 1998. Complement regulato-
ry proteins on the sperm surface: relevance to sperm 
motility. Am. J. Reprod. Immunol. 39:243–248.
 24. Inoue, N., et al. 2003. Disruption of mouse CD46 
causes an accelerated spontaneous acrosome 
reaction in sperm. Mol. Cell. Biol. 23:2614–2622.
 25. Mizuno, M., Harris, C.L., and Morgan, B.P. 2004. 
Immunohistochemical analysis of membrane 
complement regulatory proteins in rat testis: 
unique roles for DAF and MCP in spermatozoal 
function? Abstracts from the XXth International 
Complement Workshop, 172. Mol. Immunol. 
41:280.
 26. Hosokawa, M., Nonaka, M., Okada, N., and 
Okada, H. 1996. Molecular cloning of guinea pig 
membrane cofactor protein: preferential expres-
sion in testis. J. Immunol. 157:4946–4952.
 27. Foley, S., Li, B., Dehoff, M., Molina, M., and Hol-
ers, V.M. 1993. Mouse Crry/p65 is a regulator of 
the alternative pathway of complement activa-
tion. Eur. J. Immunol. 23:1381–1384.
 28. Xu, C., et al. 2000. A critical role for the murine 
complement regulator Crry in fetomaternal tol-
erance. Science. 287:498–501.
 29. Anderson, D.J., Abbott, A.F., and Jack, R.M. 1993. 
The role of complement component C3b and its 
receptors in sperm-oocyte interaction. Proc. Natl. 
Acad. Sci. U. S. A. 90:10051–10055.
 30. Taylor, C.T., Biljan, M.M., Kingsland, C.R., and 
Johnson, P.M. 1994. Inhibition of human sper-
matozoon-oocyte interaction in vitro by mono-
clonal antibodies to CD46 (membrane cofactor 
protein). Hum. Reprod. 9:907–911.
 31. D’Cruz, O.J., Lambert, H., and Haas, G.G., Jr. 1997. 
Expression of CD15 (Lewisx) antigen on human 
sperm and its role in sperm-egg interaction. Am. J. 
Reprod. Immunol. 37:172–183.
 32. Riley, R.C., Tannenbaum, P.L., Abbott, D.H., and 
Atkinson, J.P. 2002. Cutting edge. Inhibiting mea-
sles virus infection but promoting reproduction: 
an explanation for splicing and tissue-specific 
expression of CD46. J. Immunol. 169:5405–5409.
 33. Hsu, E.C., et al. 1997. Artificial mutations and 
natural variations in the CD46 molecules from 
human and monkey cells define regions important 
for measles virus binding. J. Virol. 71:6144–6154.
 34. Adams, E., Brown, M.C., Nunge, M., Krych, 
M., and Atkinson, J.P. 1991. Contribution of 
the repeating domains of membrane cofactor 
protein (CD46) of the complement system to 
ligand binding and cofactor activity. J. Immunol. 
147:3005–3011.
 35. Iwata, K., et al. 1995. Diversity of sites for measles 
virus binding and for inactivation of comple-
ment C3b and C4b on membrane cofactor pro-
tein CD46. J. Biol. Chem. 270:15148–15152.
 36. Vanderpuye, O.A., Labarrere, C.A., and McIntyre, 
J.A. 1992. The complement system in human 
reproduction. Am. J. Reprod. Immunol. 27:145–155.
 37. Clarke, G.N., Hsieh, C., Koh, S.H., and Cauchi, 
M.N. 1984. Sperm antibodies, immunoglobulins, 
and complement in human follicular fluid. Am. J. 
Reprod. Immunol. 5:179–181.
 38. Perricone, R., et al. 1992. Functionally active com-
plement is present in human ovarian follicular 
fluid and can be activated by seminal plasma. 
Clin. Exp. Immunol. 89:154–157.
 39. Perricone, R., et al. 1990. Complement, comple-
ment activation and anaphylatoxins in human 
ovarian follicular f luid. Clin. Exp. Immunol. 
82:359–362.
 40. Cervoni, F., et al. 1993. Expression of decay acceler-
ating factor (CD55) of the complement system on 
human spermatozoa. J. Immunol. 151:939–948.
 41. Fenichel, P., et al. 1994. Expression of the comple-
ment regulatory protein CD59 on human sper-
matozoa: characterization and role in gametic 
interaction. Mol. Reprod. Dev. 38:338–346.
 42. Mold, C., Gewurz, H., and Du Clos, T.W. 1999. 
Regulation of complement activation by C-reac-
tive protein. Immunopharmacology. 42:23–30.
 43. Jilma, B., et al. 1997. Menstrual cycle-associated 
changes in blood levels of interleukin-6, alpha1 
acid glycoprotein, and C-reactive protein. J. Lab. 
Clin. Med. 130:69–75.
 44. Orvieto, R., et al. 2004. C-reactive protein levels in 
patients undergoing controlled ovarian hyperstim-
ulation for IVF cycle. Hum. Reprod. 19:357–359.
 45. Liszweski, M.K., et al. 2000. Dissecting sites 
important for complement regulatory activity in 
membrane cofactor protein (MCP; CD46). J. Biol. 
Chem. 275:37692–37701.
 46. Barilla-LaBarca, M.L., Liszewski, M.K., Lambris, 
J.D., Hourcade, D., and Atkinson, J.P. 2002. Role 
of membrane cofactor protein (CD46) in regula-
tion of C4b and C3b deposited on cells. J. Immunol. 
168:6298–6304.
 47. Gershov, D., Kim, S., Brot, N., and Elkon, K.B. 
2000. C-Reactive protein binds to apoptotic 
cells, protects the cells from assembly of the 
Downloaded on June  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/23213
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 115   Number 5   May 2005 1249
terminal complement components, and sustains 
an antiinflammatory innate immune response: 
implications for systemic autoimmunity [erratum 
2001, 193:1439]. J. Exp. Med. 192:1353–1364.
 48. Vogelpoel, F.R., et al. 1987. Antibody and comple-
ment-binding activity of viable and nonviable 
human spermatozoa. Arch. Androl. 18:189–197.
 49. Cervoni, F., et al. 1992. Identification and char-
acterization of membrane cofactor protein on 
human spermatozoa. J. Immunol. 148:1431–1437.
 50. Clark, R.A., and Klebanoff, S.J. 1976. Generation 
of a neutrophil chemotactic agent by spermato-
zoa: role of complement and regulation by semi-
nal plasma factors. J. Immunol. 117:1378–1386.
 51. Vogelpoel, F.R., and Verhoef, J. 1985. Activation of 
polymorphonuclear leukocytes by spermatozoa. 
Arch. Androl. 14:123–131.
 52. Lee, Y.-L., et al. 2004. The embryotrophic activity 
of oviductal cell-derived complement C3b and 
iC3b, a novel function of complement protein in 
reproduction. J. Biol. Chem. 279:12763–12768.
 53. Wessels, M.R., et al. 1995. Studies of group B 
streptococcal infection in mice deficient in com-
plement component C3 or C4 demonstrate an 
essential role for complement in both innate and 
acquired immunity. Proc. Natl. Acad. Sci. U. S. A. 
92:11490–11494.
 54. Circolo, A., et al. 1999. Genetic disruption of the 
murine complement C3 promoter region gener-
ates deficient mice with extrahepatic expression 
of C3 mRNA. Immunopharmacology. 42:135–149.
 55. Fischer, M., et al. 1996. Regulation of the B cell 
response to T-dependent antigens by classical 
pathway complement. J. Immunol. 157:549–556.
 56. He, Z.Y., et al. 2003. None of the integrins known 
to be present on the mouse egg or to be ADAM 
receptors are essential for sperm-egg binding and 
fusion. Dev. Biol. 254:226–237.
 57. Schorey, J.S., Carroll, M.C., and Brown, E.J. 1997. 
A macrophage invasion mechanism of pathogenic 
mycobacteria. Science. 277:1091–1093.
 58. Seya, T., et al. 1991. Preferential inactivation of 
the C5 convertase of the alternative complement 
pathway by factor I and membrane cofactor pro-
tein (MCP). Mol. Immunol. 28:1137–1147.
 59. Kurita-Taniguchi, M., et al. 2002. Molecular 
assembly of CD46 with CD9, alpha 3-beta 1 
integrin and protein tyrosine phosphatase SHP-1 
in human macrophages through differentiation 
by GM-CSF. Mol. Immunol. 38:689–700.
 60. Lozahic, S., et al. 2000. CD46 (membrane cofactor 
protein) associates with multiple beta 1 integrins 
and tetraspans. Eur. J. Immunol. 30:900–907.
 61. LeNaour, F., Rubinstein, E., Jasmin, C., Prenant, 
M., and Boucheix, C. 2000. Severely reduced 
female fertility in CD9-deficient mice. Science. 
287:319–321.
 62. Miyado, K., et al. 2000. Requirement of CD9 on 
the egg plasma membrane for fertilization. Science. 
287:321–324.
Downloaded on June  9, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/23213
